Craig L. Tendler, MD, Vice President, Late Development and Global Medical Affairs for Oncology, Janssen Oncology, discusses the importance of ibrutinib's Breakthrough Therapy Designation.
Craig L. Tendler, MD
Advertisement
Articles by Craig L. Tendler, MD
Advertisement
Latest Updated Articles
Dr. Tendler on Breakthrough Designation for IbrutinibJune 26th 2013
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
The OncFive: Top Oncology Articles for the Week of 5/31
5